Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Momelotinib
Cat. No.:
OB0225LY-0362
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
Momelotinibt is an inhibitor targeting JAK1 and JAK2 and is mainly used in the study of hematologic diseases.
Synonym:
CYT11387; CYT387; LM-1149; 1056634-68-4; N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide; N-(Cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide
CAS No.:
1056634-68-4
Compound CID:
25062766
Formula:
C23H22N6O2
Formula Weight:
414.46
Specification
Relative Density:
1.292 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Momelotinib can be used to study myelodysplastic syndromes or play an important role in tumor microenvironment studies.
Library Information
Targets:
JAK family
Receptors:
JAK1; JAK2; JAK3
Pathways:
Stem cells; Apoptosis; Autophagy; Chromatin/Epigenetic; Angiogenesis; JAK/STAT signaling
Plate Number:
AOCL-5
Plate Location:
f7
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
69 mg/mL; 166.5 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
ALogP:
2.857
HBA_Count:
4
HBD_Count:
2
Rotatable Bond:
6
